EGFR Inhibitor Therapy
EGFR inhibitors are daily tablets that switch off the growth signal driving lung cancers with an EGFR mutation. A gene test decides who benefits. Osimertinib is the standard, raising five-year survival after surgery from 78 to 88 percent, and with added chemotherapy it pushed median survival in advanced disease to 47.5 months.
About This Department
One gene test decides whether lung cancer is treated with a daily tablet. For the right patient, the tablet outperforms chemotherapy.
EGFR inhibitors, a family of targeted drugs, switch off a growth signal some lung cancers depend on. They work only when the tumor carries a mutation in the EGFR gene, which a biopsy or blood test finds, and in those patients they are taken as a tablet once a day at home. Osimertinib, the current standard, gave a median survival of 38.6 months against 31.8 with older tablets in the FLAURA trial. After surgery for EGFR-mutated lung cancer it raised five-year survival from 78 to 88 percent, and combined with chemotherapy it pushed median survival to 47.5 months.
The title of this page, EGFR Inhibitor Therapy, covers a family of drugs. Most of what follows concerns non-small cell lung cancer, where these tablets changed treatment more than anywhere else. Few drugs have done more. A short note covers the antibodies of the same family used in bowel and head and neck cancer.
The drugs and how they work
One receptor, several drugs.
EGFR, the epidermal growth factor receptor, sits on the surface of cells and passes on signals to grow and divide. In some lung cancers a mutation leaves the receptor switched on permanently, so the tumor grows without waiting for a signal and comes to depend on that one pathway. EGFR inhibitors block the receptor from inside the cell. The tumor loses its engine, and in most patients with the mutation it shrinks within weeks.
This table scrolls sideways on a narrow screen. Swipe or drag to see every column.
| Drug | Generation and form | Main use |
|---|---|---|
| Gefitinib, erlotinib | First generation, daily tablet | EGFR-mutated lung cancer, now mostly replaced by osimertinib |
| Afatinib, dacomitinib | Second generation, daily tablet | EGFR-mutated lung cancer, including some uncommon mutations |
| Osimertinib | Third generation, daily tablet | The first choice in EGFR-mutated lung cancer, after surgery and in advanced disease, also active in the brain |
| Amivantamab, with or without lazertinib | Antibody by drip, with a tablet partner | EGFR exon 20 insertions and, in combination, first-line treatment |
| Cetuximab, panitumumab | Antibodies by drip | Bowel cancer without RAS mutation, and cetuximab in head and neck cancer |
The antibodies are a different story
The gene test comes first
Without the mutation the drug does harm.
Every patient with advanced non-squamous lung cancer should have the tumor tested for EGFR and the other targetable changes before any treatment starts, and guidelines now extend the test to patients having surgery. The test uses the biopsy tissue already taken, or a blood sample that looks for tumor DNA when tissue is scarce. It takes one to two weeks. The report names the exact mutation, and the name matters, because exon 19 deletions and the L858R mutation respond best, some uncommon mutations respond to particular drugs, and exon 20 insertions need a different treatment altogether.
Mutation positive, risk ratio 0.48. Mutation negative, 2.85.In IPASS, 1,217 East Asian patients with lung adenocarcinoma received gefitinib or chemotherapy, and in those with the EGFR mutation gefitinib cut the risk of progression by half. In those without it, the same tablet made progression nearly three times more likely than chemotherapy. Mok and colleagues, New England Journal of Medicine, 2009.
Starting treatment
After surgery
Twenty years of trials, in five steps
What the trials do not say
Side effects of daily tablets
Side effects come from the same receptor in the skin and the bowel, which the tablet blocks there too, and most of them cause nuisance without danger and are treated at home with creams, fluids and loperamide while the tablet continues at the full dose.
Rash in two thirds, diarrhea in almost halfWith gefitinib in IPASS, rash or acne occurred in 66.2 percent and diarrhea in 46.6 percent. Osimertinib causes the same problems, usually milder, which is one reason patients stay on it longer.
- An acne-like rash on the face, chest and back, treated with creams and antibiotic tablets, and prevented in part by moisturizer and sun protection
- Diarrhea, controlled with loperamide and fluids
- Dry skin, cracked fingertips and painful inflammation around the nails
- Mouth sores and changes in taste
- With osimertinib, inflammation of the lungs in a few percent of patients, which shows as new cough or breathlessness and needs the tablet stopped at once
- With osimertinib, changes in heart rhythm on the ECG and, rarely, weaker pumping of the heart, which is why ECGs are repeated
When the tablet stops working
Resistance arrives in nearly every patient with advanced disease. Planning for it early saves time.
A second biopsy tells the next stepA new tissue or blood test after progression looks for the reason. A MET amplification can be treated with an added drug, a transformation to small cell cancer needs chemotherapy, and patients who began on an older tablet and developed the T790M mutation move to osimertinib. When nothing targetable is found, chemotherapy with or without further drugs follows.
Length of stay, flying, cost and the trip
A tablet travels well.
What decides the cost, and the trip
Follow-up at home
Once you are back home, your oncologist there follows the written schedule in the table below. The coordinator stays reachable on the same WhatsApp number, and clinical questions go to the treating oncologist.
See a doctor the same day
This table scrolls sideways on a narrow screen. Swipe or drag to see every column.
| What | How often | Why |
|---|---|---|
| Clinic review | Every four weeks at first, then every two to three months | Side effects, weight and dose |
| Blood tests | With each review | Liver, kidney and blood counts |
| ECG | At the start and periodically on osimertinib | Heart rhythm |
| CT of chest and abdomen | Every two to three months | Response and early signs of resistance |
| Brain MRI | Every three to six months, or sooner with symptoms | Brain metastases, common in this cancer |
EGFR Inhibitor Therapy FAQ
Who can take an EGFR inhibitor?
Is osimertinib better than the older tablets?
Should chemotherapy be added to osimertinib?
How long does an EGFR inhibitor work?
What are the main side effects?
Can I take the tablets at home after starting in Istanbul?
References
- Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10):947-57.
- Ramalingam SS, Vansteenkiste J, Planchard D, et al. Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC. N Engl J Med. 2020;382(1):41-50.
- Tsuboi M, Herbst RS, John T, et al. Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC. N Engl J Med. 2023;389(2):137-147.
- Planchard D, Janne PA, Cheng Y, et al. Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC. N Engl J Med. 2023;389(21):1935-1948.
- Janne PA, Planchard D, Kobayashi K, et al. Survival with Osimertinib plus Chemotherapy in EGFR-Mutated Advanced NSCLC. N Engl J Med. 2026;394(1):27-38.
Editor's note
Written by the Biruni Hospital medical editorial team. Reviewed by Prof. Dr. Metin GÜDEN, Radiation Oncology.
Medically reviewed by
Prof. Dr. Metin GÜDEN
Radiation Oncology
Related Treatments
View All
ALK Inhibitor Therapy
ALK inhibitor therapy treats ALK-positive lung cancer with a daily tablet taken at home. In the CROWN trial 60 percent of patients on lorlatinib were free of progression at five years, alectinib cut brain progression from 45 to 12 percent in ALEX, and two years of alectinib after surgery now protects early disease.
Anti-Angiogenic Therapy
Anti-angiogenic therapy blocks VEGF, the signal tumors use to grow their own blood vessels. Bevacizumab is given by drip with chemotherapy or immunotherapy, and tablets such as sunitinib, axitinib, cabozantinib and lenvatinib are taken at home. It treats bowel, liver, kidney, ovarian, cervical, lung and thyroid cancers. Our oncologists check blood pressure, bleeding risk and surgery timing before the first dose and follow you once you are back home.
Antibody Drug Conjugate Therapy - ADC Therapy
An antibody drug conjugate links an antibody that finds cancer cells to a powerful chemotherapy drug, delivering it inside the tumor. ADCs are now standard in HER2-positive, HER2-low and triple-negative breast cancer and in advanced bladder cancer, where enfortumab vedotin with pembrolizumab raised median survival from 16.1 to 31.5 months.
Atezolizumab Therapy - Tecentriq
Atezolizumab is an immunotherapy drip that blocks PD-L1, the protein tumors use to switch off the immune cells attacking them. It is approved for lung cancer after surgery and in advanced disease, for small cell lung cancer and, with bevacizumab, for advanced liver cancer, where it raised one-year survival from 54.6 to 67.2 percent.
Bevacizumab Therapy - Avastin
Starving a tumor of new blood vessels sounds as if it should work everywhere. The trials say otherwise. Bevacizumab added months of life in bowel, lung, cervical and liver cancer, delayed ovarian cancer, and did nothing for survival in newly diagnosed glioblastoma. This guide gives each result, the side effects, the biosimilars and how a course is planned.